Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that the harlequin ichthyosis mouse model closely resembles human type 2 harlequin ichthyosis, indicating its potential as a useful model for studying the human condition.

This study found that the JAK1 inhibitors baricitinib and abrocitinib significantly reduced mechanical alloknesis in a murine model of atopic dermatitis, whereas the JAK2 inhibitor AZ960 had no effect.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

This study found that GLI2 plays a key role in activating follistatin, an activin/BMP antagonist, in response to hedgehog signaling in human epidermal cells, with implications for hair follicle development and basal cell carcinoma.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study found that the expression levels of Siah1 and Siah2 in mice skin vary dynamically during postnatal hair follicle development, suggesting their specific roles in modulating the HIF pathway.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This study suggests that tissue transglutaminase (TG2) may play a role in sebum production by regulating autophagy in sebaceous glands, offering potential targets for dermatological interventions.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This research concluded that Snail2's absence in myeloid progenitors promotes tumor progression in mice, and specific zinc fingers are crucial for Snail1 and Snail2's roles in establishing epithelial-to-mesenchymal transition.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

Type I and Type II keratin chains can form heterodimers despite sequence differences.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

This study reported that topical ω‐0‐acylceramide improved skin barrier function in Jack Russell Terriers with TGM1-deficient autosomal recessive congenital ichthyosis, normalizing skin pH and reducing transepidermal water loss.

This study demonstrated that transplanting in vitro differentiated Wharton's jelly mesenchymal stem cells on acellular dermal grafts led to complete skin regeneration with appendages in a mouse model of full-thickness wounds.

A 2 mm needle is effective and precise for skin injections.

This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This study found that JAK1 and JAK3 inhibitors effectively reversed alopecia in a mouse model of AA by reducing skin inflammation, while JAK2 inhibition did not promote hair regrowth.

This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.

This study found that human mesenchymal stem cells overexpressing JAM-A improved hair follicle structure and hair formation in mice by reducing abnormalities such as curved and zigzagged follicles.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

In this study, the researchers developed an advanced robotic system called STITCH for performing suture tasks, which completed an average of 2.93 sutures autonomously and 4.47 sutures with human intervention in physical trials.